TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06457503: Single-Arm Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Recurrent Metastatic Nasopharyngeal Carcinoma Systemic Treatment Naïve Participants

Sponsor: Coherus Oncology, Inc. · Phase: PHASE4 · Area: ONCOLOGY · Target Enrollment: 100 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$9,572,640

Rescue Site Savings

+$6,320,160

Unlock Full NCT06457503 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06457503 Rescue Dossier →